Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.

BMC Cancer · 2022 · PMC8787901 · PMID 35073851

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Combined analysis of all cell lines showed a trend towards higher cell death that did not reach significance compared to single treatment of low-dose (20 μM) or higher-dose (30 μM) carboplatin only (Fig. 4 A).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.